Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1000 participants.
Also called NCT01176565
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Beijing Tiantan Hospital
- China Medical University Hospital
- Johns Hopkins University
- Medical University of South Carolina
- National Cerebral and Cardiovascular Center, Japan
- National Institute of Neurological Disorders and Stroke
- Seoul National University Hospital
- University Hospital Heidelberg
- University of Michigan
- University of Minnesota
- Registry
-
NCT01176565
-
- Other papers using this trial's data
- Blood pressure reduction and noncontrast CT markers of intracerebral hemorrhage expansion
- Cerebral Microbleeds and the Effect of Intensive Blood Pressure Reduction on Hematoma Expansion and Functional Outcomes: A Secondary Analysis of the ATACH-2 Randomized Clinical Trial
- Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage
- Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage
- Hematoma Expansion Shift Analysis to Assess Acute Intracerebral Hemorrhage Treatments
- Impact of Renal Impairment on Intensive Blood-Pressure-Lowering Therapy and Outcomes in Intracerebral Hemorrhage: Results From ATACH-2
- Intensive Blood Pressure Lowering and DWI Lesions in Intracerebral Hemorrhage: Exploratory Analysis of the ATACH-2 Randomized Trial
- Intensive Blood Pressure Lowering in Patients with Moderate to Severe Grade Acute Cerebral Hemorrhage: Post Hoc Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-2 Trial
- Intensive Blood Pressure Reduction and Spot Sign in Intracerebral Hemorrhage: A Secondary Analysis of a Randomized Clinical Trial
- Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage
- Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage
- Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage
- Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, China, Germany, Japan, South Korea, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT01176565. Randomized; double masking; primary purpose treatment. Start 2011-05-15 (actual); primary completion 2015-12-21 (actual). Results posted on 2017-04-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
- Acronym
- ATACH-II
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- Intravenous nicardipine hydrochloride
- Lead sponsor
- University of Minnesota
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Medical University of South Carolina
- Collaborator
- Johns Hopkins University
- Collaborator
- University of Michigan
- Collaborator
- Neurocritical Care Research Network
- Collaborator
- National Cerebral and Cardiovascular Center, Japan
- Collaborator
- Japan Cardiovascular Research Foundation
- Collaborator
- Beijing Tiantan Hospital
- Collaborator
- China Medical University Hospital
- Collaborator
- University Hospital Heidelberg
- Collaborator
- Seoul National University Hospital
Record details
- Record id
cardio:ct-nct01176565- Content hash
bd2a727a6cedcfe04533197891079fbea2ef3f92cffa1203f5540fc3097d4925